Article content material
Startup funding features a Sequence A spherical led by enterprise capital corporations Pitanga, Ecoa Capital and MOV Investimentos, together with a grant from FINEP
Article content material
SÃO PAULO — Following a US$ 3 million seed funding in 2022, Nintx (Subsequent Progressive Therapeutics), a biotech firm researching and growing therapies for multifactorial ailments utilizing Brazil’s biodiversity, has simply raised a further US$ 10 million.
The investments will assist the corporate’s plans for the approaching years, which embrace accelerating the R&D of eight new drug packages (largely in partnership with firms, similar to Adeste and Centroflora, and analysis establishments, similar to CIEnP and CNPEM, which homes Sirius, one of many largest particle accelerators on the earth), hiring researchers, introducing new applied sciences, and increasing the laboratory.
Article content material
Nintx employs an modern method to tackling multifactorial ailments brought on by genetic and environmental components in addition to their interactions, particularly these mediated by the human intestine microbiome. The biotech focuses on multi-target therapies, leveraging proprietary applied sciences similar to xGIbiomics®, which simulates the gastrointestinal system, and GAIApath®, a knowledge-graph information analytics platform that maps connections between crops, pure merchandise, organic targets, the human microbiome, and multifactorial ailments.
Nintx’s enterprise mannequin entails advancing therapies to the top of preclinical research, at which level it plans to license them to giant pharmaceutical firms for scientific growth and commercialization. The workforce anticipates that the primary drug candidate might be licensed inside three years.
Traders within the Sequence A spherical embrace enterprise capital corporations Pitanga, Ecoa Capital and MOV Investimentos. Strategic companions Tiaraju and Adeste additionally invested to strengthen synergies between their companies and Nintx. Guilherme Leal, co-founder of Natura and Dengo, and Peter Andersen, from Centroflora, stay shareholders. The Sequence A funds — unprecedented for a biotech startup in Brazil’s pharmaceutical sector — are complemented with a grant of US$ 2.5 million by FINEP, a public firm that promotes and funds science, know-how and innovation.
“Within the U.S. and Europe, biopharmaceutical startups that start licensing modern medication to main pharma firms can obtain valuations within the tons of of tens of millions of {dollars}. We imagine Nintx has the potential to comply with the identical trajectory,” says Gabriel Perez from Pitanga.
“What drew our consideration was Nintx’s social and environmental influence potential, because it values biodiversity by way of agroforestry practices, investments in small farmers, and benefit-sharing agreements with communities that maintain data about these crops,” says Paulo Bellotti from MOV Investimentos.
New Management
The funding coincides with a management restructuring at Nintx. Stephani Saverio, who co-founded the corporate alongside scientists Miller Freitas and Cristiano Guimarães, assumes the position of CEO in January of 2025. Beforehand serving on the Board of Administrators, Saverio now steps into an government position.
With over 25 years of expertise in main pharmaceutical teams, Saverio leaves the place of International Vice President of Enterprise Improvement at Knight Therapeutics, a pan-American specialty pharmaceutical firm, to tackle the problem at Nintx.
Article content material
“The brand new C-level construction, the place Saverio turns into CEO, I assume the position of CDO (Chief Improvement Officer), and Cristiano stays CSO (Chief Scientific Officer), has been a part of our strategic plan for this subsequent section of the startup,” says Freitas.
“Nintx is a uncommon case in Brazil as most firms within the nation are targeted on established applied sciences, leading to an absence of world competitiveness. We’re on monitor to ascertain a biotech firm targeted on actually modern therapies—a pioneering method in Brazil’s pharmaceutical trade,” Saverio provides.
About Nintx
Nintx develops a brand new technology of medicines leveraging biodiversity, primarily from Brazil. One in all its key improvements is a broader method to tackling multifactorial ailments, brought on by genetic and environmental components in addition to their interactions by way of the human intestine microbiome. Multifactorial ailments embrace metabolic, immunological, most cancers, and mind issues. Nintx develops therapies concentrating on organic pathways straight and not directly by way of intestine microbiome modulation—each carefully linked to the onset or worsening of multifactorial ailments.
View supply model on businesswire.com: https://www.businesswire.com/information/residence/20241211877241/en/
Contacts
Nintx Contact
E-mail – information@nintx.com.br
Cellphone – +55 11 99947-9278
Press Contact
Pecan Comunicação
Vinicius Claudio – +55 47 99641-1998 / vinicius@pecancom.com.br
Patricia Cançado – +55 11 95344-0048 / patricia@pecancom.com.br
#distro
Share this text in your social community
